June 13, 2025

Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC

Neoadjuvant nivolumab plus chemotherapy significantly improved overall survival rates at 5 years compared with chemotherapy before surgery alone in patients with resectable non–small cell lung cancer ...

The ASCO Post

June 13, 2025

Breast Cancer Radiotherapy Leads to Moderate Cardiac Function Decline Over Years

Patients with breast cancer receiving radiation therapy demonstrated moderate changes in their cardiac function over a period of several years, and patients who received a maximum left anterior descen...

The ASCO Post

June 13, 2025

Prophylactic Radiation Therapy of the Contralateral Breast in BRCA Carriers with Early-Stage Breast Cancer

In a long-term follow-up of an Israeli phase II trial reported in a research letter in JAMA Oncology, Evron et al compared prophylactic radiation therapy of the contralateral breast vs surveillance in...

The ASCO Post

June 13, 2025

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care tre...

The ASCO Post

June 13, 2025

Navigational Bronchoscopy vs Transthoracic Needle Biopsy for Lung Nodules: Diagnostic Accuracy

In a study (VERITAS) reported in The New England Journal of Medicine, Lentz et al evaluated whether the diagnostic accuracy of navigational bronchoscopy was noninferior to that of transthoracic needle...

The ASCO Post

June 12, 2025

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical ...

The ASCO Post

June 11, 2025

FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer

Today, the FDA granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recu...

The ASCO Post

June 11, 2025

Evolving Role of Surgical De-escalation for Endometrial, Ovarian, Cervical, and Vulvar Cancers

For more than a decade, the field of gynecologic oncology has witnessed a movement toward surgical de-escalation through the increased use of minimally invasive surgical techniques and sentinel lymph...

The ASCO Post

June 10, 2025

AACR Statement on Former President Joseph Biden’s Cancer Diagnosis

The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis.

The ASCO Post